PAGE-B Score: Predicts 5-year hepatocellular carcinoma (HCC) risk in patients on potent HBV antivirals (TDF/ETV).
Years
Platelet Count (10³/µL)
Assigned Gender
HCC Risk Prediction
5-year HCC risk ~0%. Surveillance may not be required (per European guidelines).